



(51) International Patent Classification:

C12N 9/12 (2006.01) C12N 15/10 (2006.01)
C12N 9/22 (2006.01) C12N 15/11 (2006.01)

(21) International Application Number:

PCT/US2024/044701

(22) International Filing Date:

30 August 2024 (30.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/580,168	01 September 2023 (01.09.2023)	US
63/580,188	01 September 2023 (01.09.2023)	US
63/553,974	15 February 2024 (15.02.2024)	US
63/638,559	25 April 2024 (25.04.2024)	US

(71) Applicant: **ARBOR BIOTECHNOLOGIES, INC.**
[US/US]; 20 Acorn Park Drive, Suite 500, Cambridge,
Massachusetts 02140 (US).

(72) Inventors: **ALFONSE, Lauren E.**; c/o ARBOR
BIOTECHNOLOGIES, INC., 20 Acorn Park Drive, Suite


500, Cambridge, Massachusetts 02140 (US). **JAKIMO, Noah M.**; c/o ARBOR BIOTECHNOLOGIES, INC., 20 Acorn Park Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **MABEN, Zachary J.**; c/o ARBOR BIOTECHNOLOGIES, INC., 20 Acorn Park Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **TORGERSON, Chad D.**; c/o ARBOR BIOTECHNOLOGIES, INC., 20 Acorn Park Drive, Suite 500, Cambridge, Massachusetts 02140 (US). **WATTERS, Kyle E.**; c/o ARBOR BIOTECHNOLOGIES, INC., 20 Acorn Park Drive, Suite 500, Cambridge, Massachusetts 02140 (US).

(74) Agent: **DAVIS, Jiewen Wendy** et al.; One Financial Center, Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., Boston, Massachusetts 02111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: REVERSE TRANSCRIPTION-MEDIATED GENE EDITING SYSTEMS AND USES THEREOF

FIG. 5



(57) Abstract: A gene editing system comprising (a) a fusion polypeptide comprising a CRISPR nuclease and a reverse transcriptase, or a nucleic acid encoding the fusion polypeptide, and (b) an RNA molecule comprising a guide RNA and a reverse transcription donor RNA, or a nucleic acid encoding the RNA molecule. Also provided herein are methods of using the gene editing system for modifying target genes of interest.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*